These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8204703)

  • 1. [The effect of ursodeoxycholic acid in patients with liver cirrhosis and chronic hypertransaminasemia].
    Buongiorno G; Quaranta GM; Penna A; Guerra V; Misciagna G; Manghisi OG
    Minerva Gastroenterol Dietol; 1994 Mar; 40(1):31-6. PubMed ID: 8204703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Factors influencing the effect of ursodeoxycholic acid therapy in chronic hypertransaminasemia].
    Buongiorno G; Quaranta GM; Guerra V; Misciagna G; Manghisi OG
    Recenti Prog Med; 1992 May; 83(5):298-302. PubMed ID: 1439111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
    Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
    Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
    Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
    Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice.
    Pelletier G; Roulot D; Davion T; Masliah C; Causse X; Oberti F; Raabe JJ; Van Lemmens C; Labadie H; Serfaty L;
    Hepatology; 2003 Apr; 37(4):887-92. PubMed ID: 12668982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
    Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M
    Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study on the hemodynamic effect of short-term ursodeoxycholic acid therapy in patients with stable liver cirrhosis.
    Baruch Y; Assy N; Weisbruch F; Reisner SA; Rinkevich D; Enat R; Blendis LM; Bomzon A
    Am J Gastroenterol; 1999 Oct; 94(10):3000-4. PubMed ID: 10520859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ursodeoxycholic acid in the therapy of chronic hepatitis after treatment with interferon].
    Porcaro G; Sannino C; Mastroianni M; Ciavattone A; Bartiromo D; Nascia S
    Minerva Med; 2000; 91(7-8):141-5. PubMed ID: 11155462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial.
    Bellentani S; Tabarroni G; Barchi T; Ferretti I; Fratti N; Villa E; Manenti F
    J Hepatol; 1989 Jan; 8(1):7-12. PubMed ID: 2564011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.